Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

BACKGROUND AND PURPOSE: Impaired ambulation is a prominent disabling symptom of multiple sclerosis and can lead to reduced quality of life. Whether natalizumab, a monoclonal antibody shown to reduce disease activity in relapsing−remitting multiple sclerosis, could impact ambulation performance was e...

Descripción completa

Detalles Bibliográficos
Autores principales: Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365753/
https://www.ncbi.nlm.nih.gov/pubmed/25511792
http://dx.doi.org/10.1111/ene.12618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365753/
https://www.ncbi.nlm.nih.gov/pubmed/25511792
http://dx.doi.org/10.1111/ene.12618

Ejemplares similares